News | May 15, 2026
Lilly and UNICEF launch $50M push to reach 30 million children with life-saving health care
The target reach is of more than 30 million young people and caregivers across 21 countries
The target reach is of more than 30 million young people and caregivers across 21 countries
The test is designed to help clinicians either rule in or rule out amyloid pathology in patients showing signs of cognitive decline
Lifts full-year outlook as obesity drug boom accelerates
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
The ninth edition of the event brought together over 800 delegates, more than 60 national and international speakers, and 20+ partner organisations across 10 sessions
At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
The expanded program allows patients to fill prescriptions either at a local pharmacy or through home delivery via LillyDirect
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
